Alnylam Pharmaceuticals Inc. (ALNY) rolled out its "Alnylam 2030" strategy over the weekend, laying out an aggressive five-year plan that's basically a bet on scale, science, and doubling down on what's already working.

The biotech has a track record here. Management pointed out that the company met or exceeded every objective in its previous P5x25 plan, which gives this new roadmap some credibility beyond the usual corporate aspirational talk.

TTR Takes Center Stage

The heart of the strategy is establishing what Alnylam calls "durable global leadership" in transthyretin diseases. That means aiming to lead the TTR market in revenue by decade's end, both on a single-year basis and cumulatively over the next five years.

The company's banking on nucresiran, a next-generation RNAi therapy expected to launch for polyneuropathy by 2028 and cardiomyopathy by 2030, to cement that position.

But Alnylam isn't putting all its eggs in the TTR basket. The plan calls for at least two additional blockbuster-potential medicines outside TTR indications, expansion into 10 different tissue types, and running more than 40 clinical programs simultaneously. The company plans to reinvest roughly 30% of revenue into non-GAAP research and development.

The Numbers Behind the Vision

By 2030, Alnylam is targeting compound annual revenue growth north of 25% and non-GAAP operating margins around 30%.

The preliminary fourth-quarter numbers show momentum building. Amvuttra and Onpattro, the company's TTR franchise products, brought in about $827 million and $32 million respectively in the quarter, driving 151% year-over-year growth for the franchise.

For the full year 2025, Amvuttra reached approximately $2.3 billion and Onpattro hit $173 million, more than doubling from 2024 levels. The rare disease products Givlaari and Oxlumo combined for roughly $137 million in the fourth quarter, with full-year sales landing around $499 million.

2026 Outlook Exceeds Expectations

Looking ahead, Alnylam guided for 2026 combined net product revenue between $4.9 billion and $5.3 billion, reflecting 71% growth at the midpoint. Breaking it down by franchise, the company expects the TTR franchise to generate $4.4 billion to $4.7 billion, representing 83% growth at the midpoint, while the rare disease franchise should hit $500 million to $600 million, reflecting 10% growth at the midpoint.

Analysts noted that while 2025 net product revenues came in slightly below expectations, the 2026 guidance significantly exceeded Street estimates.

ALNY Price Action: Alnylam Pharmaceuticals shares were down 10.07% at $358.20 at the time of publication on Monday.